Advertisement

Uterine Cancer pp 251-265 | Cite as

Management of Uterine Sarcomas

  • Carolyn KrasnerEmail author
  • Martee L. Hensley
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Leiomyosarcomas, endometrial stromal sarcomas, and carcinosarcomas differ widely in tumor biology, and their treatment is being addressed in separate trials. Unfortunately, therapeutic progress is slow because of the relatively rarity of these tumors. Recent trials using well defined patient populations are helping to define effect hormonal and chemotherapeutic strategies.

Keywords

Uterine sarcomas Carcinosarcoma Leiomyosarcoma Gemcitabine Docetaxel Hormones 

References

  1. 1.
    Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results: analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004;93:204.PubMedCrossRefGoogle Scholar
  2. 2.
    Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer 1997;33 (6):907–911.PubMedCrossRefGoogle Scholar
  3. 3.
    Rha SE, Byun JY, Jung SE, et al. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol 2003;181:1369–1374.PubMedGoogle Scholar
  4. 4.
    Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460–469.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782–2786.PubMedCrossRefGoogle Scholar
  6. 6.
    Major FJ, Blessing JA, Silverberg SG, et al Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702–1709.PubMedCrossRefGoogle Scholar
  7. 7.
    Ferrer F, Sabater S, Farrus, B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB. Mixed mullerian tumors of the uterus: a clinicopathologic study. Obstet Gynecol 1989;74:388–392.PubMedGoogle Scholar
  9. 9.
    Silverberg SG, Major FJ, Blessing JA, et al Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–19.PubMedCrossRefGoogle Scholar
  10. 10.
    Kahanpaa KV, Wahlstrom T, Grohn P, Heinonen E, Nieminen U, Widholm O. Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 1986;67(3):417–424.PubMedGoogle Scholar
  11. 11.
    Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83(3):414–418.PubMedGoogle Scholar
  12. 12.
    Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JLJR. Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988;71:845–850.PubMedGoogle Scholar
  13. 13.
    O’Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol 1990;21(2):223–227.PubMedCrossRefGoogle Scholar
  14. 14.
    Goff BA, Rice LW, Fleischhacker D, et al Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993;50:105–109.PubMedCrossRefGoogle Scholar
  15. 15.
    Berchuck A, Rubin SC, Hoskins WJ, Soisson PA, Bast RC JR , Boyer CM. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathologic study of 53 endometrial stromal tumors. Cancer 1966;19(6):755–766.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolfson AH, Brady MF, Rocereto TF, et al A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide+mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus. Proc Amer Soc Clin Oncol 2006;24:5001, Abstract #185.Google Scholar
  18. 18.
    Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127–2130.PubMedCrossRefGoogle Scholar
  19. 19.
    Podczaski ES, Woomert CA, Stevens CW, Jr, et al Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol 1989;32:240–244.PubMedCrossRefGoogle Scholar
  20. 20.
    Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed mullerian tumors of the uterus: Analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786–796.PubMedCrossRefGoogle Scholar
  21. 21.
    Spanos WJ Jr , Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 1986;57:155–159.PubMedCrossRefGoogle Scholar
  22. 22.
    Major FJ, Blessing JA, Silverberg SG, et al Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702–1709.PubMedCrossRefGoogle Scholar
  23. 23.
    Gadducci A, Landoni F, Sartori, E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Gadducci A, Sartori E, Landoni F, et al Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;63:247–253.PubMedCrossRefGoogle Scholar
  25. 25.
    Salazar OM, Bonfiglio TA, Patten SE, et al Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978;42:1161–1170.PubMedCrossRefGoogle Scholar
  26. 26.
    Knocke TH, Kucera H, Dorfler D, Pokrajac B, Potter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998;83(9):1972–1979.PubMedCrossRefGoogle Scholar
  27. 27.
    Sorbe B. Radiotherapy and/or chemotherapy as adjuvant therapy of uterine sarcomas. Gyncol Oncol 1985;20:281–289.CrossRefGoogle Scholar
  28. 28.
    Omura GA, Blessing JA, Major F, et al A randomized clinical trial of adjuvantadriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1240–1245.PubMedGoogle Scholar
  29. 29.
    Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127–2130.PubMedCrossRefGoogle Scholar
  30. 30.
    Ferrer F, Sabater S, Farrus B, et al Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001;49(3):739–748.PubMedCrossRefGoogle Scholar
  32. 33.
    National Comprehensive Cancer Network guidelines available online at www.nccn.org/professionals/physician_gls/default.asp.Google Scholar
  33. 33.
    Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol 1988;38:233–239.PubMedCrossRefGoogle Scholar
  34. 34.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol 2000;78:221–227.PubMedCrossRefGoogle Scholar
  35. 35.
    Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical Stage I and II malignant mixed Mullerian tumors of the uterus. Cancer 2001;91:1437–1443.PubMedCrossRefGoogle Scholar
  36. 36.
    Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol 1989;34:323–327.PubMedCrossRefGoogle Scholar
  37. 37.
    van Nagell JR, Jr, Hanson MB, Donaldson ES, Gallion HH. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer 1986;57:1451–1454.Google Scholar
  38. 38.
    Hannigan, EV, Freedman, RS, Elder, KW, Rutledge, FN. Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol 1983;16:101–104.PubMedCrossRefGoogle Scholar
  39. 39.
    Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol 1983;15:224–229.PubMedCrossRefGoogle Scholar
  40. 40.
    Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Gynecologic Oncology Group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;9:630–634.CrossRefGoogle Scholar
  41. 41.
    Pautier P, Rey A, Haie-Meder C, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 2004;14:1112–1117.PubMedCrossRefGoogle Scholar
  42. 42.
    Wolfson AH, Brady MF, Mannel RS et al. A gynecologic oncology group randomized trial of whole abdominal irradiation vs cisplatin-iforfamide + mesna in optimally debulked stage I–IV carcinosarcoma of uterus.Google Scholar
  43. 43.
    Hensley ML, Maki R, Venkatraman E, et al Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a Phase II trial. J Clin Oncol 2002;20:2824–2831.PubMedCrossRefGoogle Scholar
  44. 44.
    Reich O, Regauer S, Urdl W, Lahousen M, Winter R. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 2000;82:1030–1034.PubMedCrossRefGoogle Scholar
  45. 45.
    Leitao MM, Soslow RA, Nonaka D, et al Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455–1462.PubMedCrossRefGoogle Scholar
  46. 46.
    Mountain CF, McMurtrey MJ, Hermes RF. Surgery for pulmonary metastases: a 20-year experience. Ann Thorac Surg 1984;38:323–330.PubMedCrossRefGoogle Scholar
  47. 47.
    Levenback C, Rubin SC, McCormack PM, Hoskins WJ, Atkinson EN, Lewis JL, Jr. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992;45:202–205.PubMedCrossRefGoogle Scholar
  48. 48.
    Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Spanos W, Guse C, Perez C, Grisby P, Doggett RL, Poulter C. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys 1989;17:659–661.PubMedCrossRefGoogle Scholar
  50. 50.
    Omura GA, Major FJ, Blessing JA, et al A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626–632.PubMedCrossRefGoogle Scholar
  51. 51.
    Muss HB, Bundy B, DiSaia PJ, et al Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a Phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648–1653.PubMedCrossRefGoogle Scholar
  52. 52.
    Sutton G, Brunetto VL, Kilgore L, et al A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000;79:147–153.PubMedCrossRefGoogle Scholar
  53. 53.
    Sit AS, Price FV, Kelley JL, et al Chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2000;79:196–200.PubMedCrossRefGoogle Scholar
  54. 54.
    Antman K, Crowley J, Balcerzak SP, et al An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276–1285.PubMedGoogle Scholar
  55. 55.
    Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW.Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol 1996;61:27–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Piver MS, DeEulis TG, Lele SB, Barlow JJ. Cyclophosphamide, vincristine, adriamycin and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital track. Gynecol Oncol 1982;14:319–323.PubMedCrossRefGoogle Scholar
  57. 57.
    Sabini G, Chumas JC, Mann WJ. Steroid hormone receptors in endometrial stromal sarcoma. A biochemical and immunohistochemical study. Am J Clin Pathol 1992;97(3):381–386.PubMedGoogle Scholar
  58. 58.
    Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2001;83:268–270.PubMedCrossRefGoogle Scholar
  59. 59.
    xxx, Proc Am Soc Clin Oncol 2006, abstGoogle Scholar
  60. 60.
    McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321–325.PubMedCrossRefGoogle Scholar
  61. 61.
    George E, Manivel JC, Denher LP, Wick MR. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 1991 Mar;22(3):215–223.PubMedCrossRefGoogle Scholar
  62. 62.
    Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989;161:309–312.PubMedGoogle Scholar
  63. 63.
    Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962–1966.PubMedGoogle Scholar
  64. 64.
    Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:217–221.PubMedCrossRefGoogle Scholar
  65. 65.
    Fowler JM, Blessing JA, Burger RA, Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2002;85:311–314.PubMedCrossRefGoogle Scholar
  66. 66.
    Slayton RE, Blessing JA, Clarke-Pearson D. A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study. Invest New Drugs 1991;9:93–94.PubMedGoogle Scholar
  67. 67.
    Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002;85:459–463.PubMedCrossRefGoogle Scholar
  68. 68.
    Toyoshima M, Akahira J, Matsunaga G, et al Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004;94:774–778.PubMedCrossRefGoogle Scholar
  69. 69.
    xxx, Proc Am Soc Clin Oncol 2006, abstGoogle Scholar
  70. 70.
    Thigpen T, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962–1966.PubMedGoogle Scholar
  71. 71.
    Muss HB, Bundy BN, Adcock L, Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990 Feb;13(1):32–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Omura GA, Major FJ, Blessing JA, et al A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52(4):626–632.PubMedCrossRefGoogle Scholar
  73. 73.
    Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:749–752.PubMedCrossRefGoogle Scholar
  74. 74.
    Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556–559.PubMedGoogle Scholar
  75. 75.
    Look KY, Sandler A, Blessing JA, et al Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004;92:644–647.PubMedCrossRefGoogle Scholar
  76. 76.
    Garcia-Carbonero R, Supko JG, Manola J, et al Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480–1490.PubMedCrossRefGoogle Scholar
  77. 77.
    Delaloge S, Yovine A, Taamma A, et al Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001;19:1248–1255.PubMedGoogle Scholar
  78. 78.
    Hensley ML, Maki R, Venkatraman E, et al Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a Phase II Trial. J Clin Oncol 2002;20:2824–2831.PubMedCrossRefGoogle Scholar
  79. 79.
    Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 1996;87:747–750.PubMedCrossRefGoogle Scholar
  80. 80.
    Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 1990;39:364–367.PubMedCrossRefGoogle Scholar
  81. 81.
    Berchuck A, Rubin, SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL, Jr. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60–65.PubMedCrossRefGoogle Scholar
  82. 82.
    Lin YC, Kudelka AP, Tresukosol D, et al Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. Gyencol Oncol 1995;58:262–265.CrossRefGoogle Scholar
  83. 83.
    Baker VV, Walton LA, Fowler WC, Jr, Currie JL. Steroid receptors in endolymphatic stromal myosis. Obstet Gynecol 1984;63:72S–74S.PubMedGoogle Scholar
  84. 84.
    Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 2003;90:170–176.PubMedCrossRefGoogle Scholar
  85. 85.
    Spano JP, Soria JC, Kambouchner M, et al Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 2003;20:87–93.PubMedCrossRefGoogle Scholar
  86. 86.
    Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 2001;82:384–388.PubMedCrossRefGoogle Scholar
  87. 87.
    Leunen, M, Breugelmans, M, De Sutter, P, et al. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 2004;95:769.PubMedCrossRefGoogle Scholar
  88. 88.
    Mesia AF, Demopoulos RI. Effects of leuprolide acetate on low-grade endometrial stromal sarcoma. Am J Obstet Gynecol 2000;182:1140–1141.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Medical Oncology, Gillette Center for Women’s CancersMassachusetts General HospitalBoston

Personalised recommendations